ReviewBiochemical pharmacology2024
Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention/therapy.
Review in Biochemical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Efficacy and safety of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Predicting taxane-induced peripheral neuropathy by nailfold capillaroscopy: The CAPNEU pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Mast cell-specific receptor MrgprB2 selectively mediates oxaliplatin-induced neuropathic pain.Journal of translational medicine · 2026Article
- Using an integrated omics approach to uncover the mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN).Communications medicine · 2026Review
- Thematic evolution and research trends in chemotherapy-induced peripheral neuropathy: a bibliometric and visual analysis from 1992 to 2024.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Article
- Analysis of the circRNA/lncRNA-miRNA-mRNA Networks of Action of Fire Needle Acupuncture in Relieving Chemotherapy-Induced Neuropathic Pain.Journal of pain research · 2026Article
- Redefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management.International journal of molecular sciences · 2025Review
- Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients-A New Promise? Preliminary Results.Cancers · 2025Article
- Review
- Multiday intravenous ketamine infusion therapy for the management of central sensitisation syndrome secondary to chronic chemotherapy-induced peripheral neuropathic pain.BMJ case reports · 2025Article
- Recent Advances in Diagnosis, Management, Treatment, and Prevention of Neuropathies in Cancer Patients.Current neurology and neuroscience reports · 2025Review
- Bortezomib-induced peripheral neuropathy: from molecular mechanisms to clinical management.Frontiers in pharmacology · 2025Review
- Innate immunity in chemotherapy-induced peripheral neuropathy: recent advances.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- Paclitaxel alters the microvascular network in the central and peripheral nervous system of rats with chemotherapy-induced painful peripheral neuropathy.Journal of the peripheral nervous system : JPNS · 2024Article
- Centralizing the Knowledge and Interpretation of Pain in Chemotherapy-Induced Peripheral Neuropathy: A Paradigm Shift towards Brain-Centric Approaches.Brain sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating sequela that is difficult for both clinicians and cancer patients to manage. Precise mechanisms of CIPN remain elusive and current clinically prescribed therapies for CIPN have limited efficacy. Recent studies have begun investigating the interactions between the peripheral and central nervous systems and the immune system. Understanding these neuroimmune interactions may shift the paradigm of elucidating CIPN mechanisms. Although the contribution of immune cells to CIPN pathogenesis represents a promising area of research, its fully defined mechanisms have not yet been established. Therefore, in this review, we will discuss (i) current shortcoming of CIPN treatments, (ii) the roles of neuroimmune interactions in CIPN development and (iii) potential neuroimmune interaction-targeting treatment strategies for CIPN. Interestingly, monocytes/macrophages in dorsal root ganglia; microglia and astrocytes in spinal cord; mast cells in skin; and Schwann cell near peripheral nerves have been identified as inducers of CIPN behaviors, whereas T cells have been found to contribute to CIPN resolution. Additionally, nerve-resident immune cells have been targeted as prevention and/or therapy for CIPN using traditional herbal medicines, small molecule inhibitors, and intravenous immunoglobulins in a preclinical setting. Overall, unveiling neuroimmune interactions associated with CIPN may ultimately reduce cancer mortality and improve cancer patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.